Funder
Pfizer
Gilead Sciences
Bristol-Myers Squibb
ViiV Healthcare
Merck
AbbVie
Abbott Laboratories
Bill and Melinda Gates Foundation
Department of Health and Ageing, Australian Government
Reference25 articles.
1. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV;Gallant;N Engl J Med,2006
2. Haas D, Hicks C, Seekins D et al. A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz in combination with open-label zidovudine with lamivudine at 36 weeks. International Conference on AIDS 1998 Geneva, Switzerland, abstract number 698.
3. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection;De Clercq;Antiviral Res,1998
4. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis;López-Cortés;Clin Pharmacokinet,2002
5. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy;Boulle;JAMA,2008
Cited by
142 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献